HMB supplementation
Dietary SupplementGroup taking oral HMB free acid supplementation in a blinded liquid form.
NCT Number: NCT05444959
The study aims at assessing the influence of β-hydroxy-β-methylbutyrate (HMB) free acid supplementation (90 mg/kg of fat free body mass/day) supplemented for 21 days on protein kinases activity and selected hormones levels, and subsequent improvements in muscle protein synthesis, lean body mass content and aerobic capacity.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 2 / Phase 3
Department of Physiology and Biochemisty at the Faculty of Physical Education and Sport (Charles University, Prague, Czech Republic), Prague, Prague 6, Czechia
The main aim of the project is to assess the effects of 21 days of HMB (90 mg/kg of fat free body mass per day) or Placebo (PLA) supplementation under two distinct exercise/stress stimulus conditions in the groups of exercise trained participants (S group) and individuals showing features of malnutrition (W group) on the activity of Akt/PBK/mTOR/p70S6K and MAPK/ERK protein kinase pathway in peripheral blood mononuclear cells and muscle; blood concentrations of free and total testosterone, cortisol, IGF-1 and growth hormone; level of resting and exercise energy metabolism rate and alternations in energy sources utilization during exercise, as well as aerobic capacity and body composition.
The study is a double-blind, randomized, placebo-controlled, parallel-group trial. The study protocol consists of two 21-days supplementation periods. Within the first period of the trial the participants will follow their customary physical exercise (S group) / lifestyle (W group). In turn, in the second period of the trial the routine training (S group) or customary lifestyle (W group) will be supplemented twice a week with a functional training program, as a source of an additional exercise/stress stimulus.
Investigators aim to recruit 60 exercise trained individuals (S group) and 60 will be inactive individuals showing features of malnutrition (W group). Random allocation of participants to the HMB and PLA treatments will be done using a random sequence generator, with groups being equalised by fat-free mass level (within S group and W group separately).
At the first preliminary visit anthropometric measurements, and familiarization with exercise test procedures [i.e., incremental cycling test with ergorespirometry, maximal voluntary isometric contraction test (MVIC; performed in a Biodex isokinetic dynamometer)] will be performed. After the completion of the preliminary tests, the participants within S group and W group will be divided randomly into two treatments: 90mg/kgFFM per day of HMB or the same amount of PLA. There will be two 21-days supplementation periods differing in the type of exercise/stress stimulus of the organism.
Before the start of supplementation period (T1) and after their completion (T2 and T3) the series of testing procedures will be performed, each of the series will consist of one day. Each testing series (T1, T2, and T3) will include anthropometric measurements followed by pre-exercise (pre-Ex) blood collection (for the determination of the activity of signaling protein kinases in peripheral blood mononuclear cells; hormone concentrations: free and total testosterone, cortisol, IGF-1 and growth hormone; concentrations of alternative energy sources: ketone bodies <acetoacetate and beta-hydroxybutyrate> and free fatty acids; activity of selected enzymes: lactate dehydrogenase <LDH>, and creatine kinase <CK>; gasometric indices: pH, pCO2, pO2 and electrolytes: Ca2+, Na+, K+, Cl-; concentrations of other biochemical indices: myoglobin, urea, creatinine, glucose, lactate, bilirubins ), the m. vastus lateralis ultrasound and collection of the m. vastus lateralis samples using the percutaneous muscle microbiopsy technique (for the determination of the activity of signaling protein kinases). After the resting pre-Ex procedures, the ICT will be performed. Then the post-exercise (post-Ex) blood sampling and second muscle microbiopsy will be carried out. Finally, at the end of the procedures the MVIC will be assessed.
After collection all the data, comparisons between supplementation treatment conditions (HMB vs PLA) within groups and supplementation periods, as well as comparisons between studied groups (S group vs W group) within supplementation treatment and supplementation period will be performed using T-test for independent variables. Comparisons between supplementation periods within studied groups and supplementation treatment will be performed via T-test for dependent variables. Statistical analysis will be performed using Statistica v. 13.3, StatSoft Polska Sp. z o.o., 2022.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Group taking oral HMB free acid supplementation in a blinded liquid form.
Group taking oral supplementation with placebo (in a blinded liquid form).
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
AKTser473, mTORSer2448, p70S7K1Thr389, 4E-BP1Ser65/Thr70, and 4EBP1Thr37/46 kinase activity (optical density)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Muscle cholesterol and mevalonate content (units)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Blood free and total testosterone, cortisol, IGF-1, growth hormone content
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
CK and LDH activity (IU)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Body mass, fat free mass, fat mass (kg)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
VO2max level (mL/min)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Body water content (L)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Blood concentrations of : myoglobin (mmol/L), urea (mmol/L), creatinine (mmol/L), glucose (mmol/L), lactate (mmol/L), bilirubins (mmol/L), and electrolytes [Ca2+, Na+, K+, Cl-] (mmol/L)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Utilization of energy substrates - fats, carbohydrate and protein during rest and exercise (g/min)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Energy expenditure during rest and exercise (kcal/min)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Daily energy expenditure (kcal/day)
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Number of repetitions of five different exercise - sumo deadlift high-pulls, wall ball shots, box jumps, push press and rowing on an ergometer in each of three exercise rounds and total number of repetitions of all exercises of all exercise rounds (reps
Time frame: Day 0 [Baseline (before treatment)] and after 21 days of each two supplementation periods
Maximum voluntary isometric contraction (MVIC) torque (Nm)
Poznan University of Physical Education
Other
Evaluation of the Impact of Exercise / Stress Stimuli on the Mechanisms and Efficacy of Beta-hydroxy-beta-methylbutyric Acid (HMB) in Trained and Malnourished Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06390670
Aerobic Capacity, Biochemical Markers
Poznan, Wielkopolska, Poland
View Trial DetailsNCT07252778
Aerobic Capacity, Biochemical Markers
Poznan, Wielkopolska, Poland
View Trial DetailsNCT03406065
Sport, Supplementation
Poznan, Wielkopolska, Poland
View Trial DetailsNCT03165357
Sport, Supplementation
Poznan, Wielkopolska, Poland
View Trial Details